Recalled Medicines & supplements – Current GIS Alerts 2026
Found 700 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
FOSIDAL O SMAKU POMARAŃCZOWYM
An unfavorable benefit-risk ratio was identified for the active substance fenspiride, posing a potential threat to patients’ health or life, justifying immediate suspension of marketing and a temporary ban on placing the product on the market. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
Unfavourable benefit–risk balance of the active substance fenspiride indicated by non-clinical studies. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
Unfavourable benefit-risk ratio for the active substance fenspiride; potential public health hazard. Potential effects: serious adverse reactions, risk to health or life.
EURESPAL
Unfavourable benefit-risk ratio for the active substance fenspiride; the French agency ANSM initiated an urgent EU re-evaluation procedure. Potential effects: deterioration of health, risk of complications.
EUREFIN
Unfavourable benefit–risk ratio for the active substance fenspiride identified from non-clinical studies; an EU review procedure initiated. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
Unfavourable benefit-risk balance for the active substance fenspiride, which may pose a public health risk and requires reassessment. Potential effects: serious adverse reactions, risk to health or life.
BUDIXON NEB
Test results out of specification in archival samples concerning the content of budesonide related substances. Potential effects: reduced efficacy, increased risk of adverse reactions.
BENODIL
Out-of-specification results for related substances of budesonide. Potential effects: reduced efficacy or altered safety of use.
BUDIXON NEB
Out-of-specification results for the content of budesonide-related substances. Potential effects: reduced efficacy or increased risk of adverse reactions.
BENODIL
Test results out of specification: elevated related substances content of budesonide. Potential effects: reduced efficacy, increased risk of adverse reactions.
BDS N
Out-of-specification results for the content of related substances of budesonide. Potential effects: reduced efficacy or safety of the medicinal product.
APO-LOZART
Detected contamination with N-nitroso-N-methylamino butyric acid (NMBA) in some batches of the losartan potassium active substance. Potential effects: carcinogenicity, increased long-term health risk.
LOREBLOK
Contamination with N-nitroso-N-methylamino butyric acid (NMBA) was detected in some batches of the losartan active substance (from Hetero Labs Limited). Potential effects: increased risk of carcinogenic effects with long-term exposure.
LOREBLOK HCT
Detection of contamination: N-nitroso-N-methylamino-butyric acid (NMBA) in the active substance losartan. Potential effects: long-term carcinogenic risk.
APO-LOZART
Detected contamination of the active substance with N-nitroso-N-methylamino-butyric acid (NMBA), an N-nitrosamine that may affect human health and life. Potential effects: increased cancer risk, systemic toxic effects.
SYDAFED XYLOSPRAY HA
It cannot be excluded that the product batch fails to meet quality requirements regarding sterility. Potential effects: risk of infections or other health complications.
IRPRESTAN
Detection of N-nitrosodiethylamine (NDEA) above the acceptable limit in the active substance sourced from Zhejiang Huahai. Potential effects: carcinogenic action and long-term health risk.
PECFENT
Suspected defect in the primary packaging of the PecFent batch, potentially causing loss of seal/integrity. Potential effects: incorrect dose (evaporation of solution), risk to health and life.
XALOPTIC FREE
Does not meet specification: elevated impurity content — 15(5)-latanoprost, single unknown impurities and increased sum of unknown and total impurities. Potential effects: risk of adverse reactions or reduced efficacy.
FLUCINAR N
Out-of-specification result in a reference sample — impurities originating from fluocinolone acetonide. Potential effects: reduced efficacy, skin adverse effects (irritation, allergic reactions).
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.